Guardian Pharmacy Services, Inc.
NYSE:GRDNMedical - Distribution
+$0.17 today
- Market cap
- $3.09B
- Beta
- 0.08
- P/E (TTM)
- 52.0
- EPS (TTM)
- $0.84
Volume 0.45M
Average 0.48M
GRDN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Guardian Pharmacy Services, Inc.NYSE: GRDN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of $35.75M rose 95.9% year over year, behind the +392.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 46.4% from the prior quarter. Over 3 fiscal years it compounded at +12.3% a year.
Context
- EBITDA amounted to 6.7% of revenue in FY2025, up 3.1 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $144.88M (+50.2%) for the fiscal year ending Dec 2026, a slowdown from the +322.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $35.75M+46.4% QoQ
- Last fiscal yearDec 2025
- $96.42M+322.0% YoY
- LTMJun 2026
- $119.81M+392.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +95.9% | +50.6% | -45.3 pp |
| 1 year | +322.0% | +50.2% | -271.8 pp |
| 3-year CAGR | +12.3% | +22.0% | +9.7 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 96.42M USD
- Year-over-year change
- +322.0%
- 4-year CAGR
- +20.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 96.42M | +322.0% |
| FY2024 | 2024-12-31 | (43.43M) | -173.8% |
| FY2023 | 2023-12-31 | 58.81M | -13.7% |
| FY2022 | 2022-12-31 | 68.15M | +46.6% |
| FY2021 | 2021-12-31 | 46.49M | — |
EBITDA vs competitors
How GRDN compares with its peers on the latest reported figures
- GRDN's LTM Jun 2026 EBITDA of $119.81M is the 3rd highest of the 11 companies compared; the peer median is -$102.28M.
- Its year-over-year change of +392.0% is the highest of 11, against a peer median of -8.7%.
- EBITDA amounts to 8.2% of revenue for GRDN, versus a peer median of 28.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $250.01M | -3.2% | +20.5% | 12.8% | |
| LTM Sep 2026 | $207.86M | +10.1% | +46.3% | 13.1% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $119.81M | +392.0% | +12.3% | 8.2% |
| LTM Sep 2026 | $37.56M | +221.9% | — | 6.1% | |
| LTM Jun 2026 | -$45.01M | +22.6% | — | 37.4% | |
| LTM Mar 2026 | -$92.11M | -14.2% | — | 28.6% | |
| LTM Mar 2026 | -$112.45M | -48.6% | — | 520.3% | |
| LTM Jun 2026 | -$127.04M | +36.8% | — | 74.8% | |
| LTM Sep 2026 | -$129.8M | -149.9% | — | 28.3% | |
| LTM Sep 2026 | -$200.94M | -29.7% | — | — | |
| LTM Mar 2026 | -$548.8M | -290.2% | — | 20.7% | |
| Peer median (excluding GRDN) | -$102.28M | -8.7% | +33.4% | 28.3% | |
Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 792.07M | 908.91M | 1.05B | 1.23B | 1.45B |
| Cost of Revenue | 630.81M | 723.04M | 837.88M | 984.04M | 1.17B |
| Gross Profit | 161.27M | 185.87M | 208.31M | 244.37M | 282.04M |
| Gross Margin | 20.4% | 20.4% | 19.9% | 19.9% | 19.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 131.12M | 133.88M | 167.36M | 307.29M | 193.13M |
| Operating Expenses | 131.12M | 133.88M | 167.36M | 307.29M | 193.13M |
| Depreciation & Amortization | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| EBITDA | 46.49M | 68.15M | 58.81M | (43.43M) | 96.42M |
| EBITDA Margin | 5.9% | 7.5% | 5.6% | -3.5% | 6.7% |
| Operating Income | 30.15M | 51.99M | 40.95M | (62.92M) | 88.91M |
| Operating Margin | 3.8% | 5.7% | 3.9% | -5.1% | 6.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.64M | 1.93M | 2.86M | 3.28M | 665K |
| Other Income / Expenses | (1.82M) | (2.33M) | (3.23M) | (3.56M) | (15.49M) |
| Income Before Tax | 28.33M | 49.66M | 37.72M | (66.48M) | 73.42M |
| Pre-Tax Margin | 3.6% | 5.5% | 3.6% | -5.4% | 5.1% |
| Income Tax Expense | 0 | 0 | 0 | 4.56M | 24.47M |
| Net Income | 16.31M | 35.42M | 23.9M | (87.29M) | 49.22M |
| Net Margin | 2.1% | 3.9% | 2.3% | -7.1% | 3.4% |
| EPS (Basic) | 0.27 | 0.58 | 0.39 | (1.77) | 0.79 |
| EPS (Diluted) | 0.27 | 0.58 | 0.39 | (1.77) | 0.78 |
| Weighted Avg Shares | 60.84M | 60.84M | 60.84M | 62.01M | 62.39M |
| Weighted Avg Shares (Diluted) | 60.84M | 60.84M | 60.84M | 62.01M | 63.3M |
Guardian Pharmacy Services, Inc.
NYSE:GRDN
Intrinsic Alpha fair value
Locked
Current Price
$48.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.